Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Sodium hydride | HCID 24758 | — |
| Reactant | HCID 21865085 | HCID 21865085 | — |
| Reactant | [1-(2-Hydroxy-ethyl)-piperidin-4-yl]-carbamic acid tert-butyl ester | HCID 45076484 | — |
| Solvent | Dimethylformamide | HCID 6228 | — |
| Product | HCID 66747473 | HCID 66747473 | 50.4% |
Reaction Steps
Sodium hydride (98% purity, 148 mg, 6.10 mmol, 1.5 eq) is added at room temperature to a stirred solution of 2-chloro-8-methoxy-quinoxaline (800 mg, 4.07 mmol, 1.0 eq) in N,N-dimethylformamide (80 mL), followed by [1-(2-hydroxy-ethyl)-piperidin-4-yl]-carbamic acid tert-butyl ester (1.17 g, 4.07 mmol, 1.0 eq). After 15 hours stirring at room temperature and 4 hours at 80° C., solvent is evaporated, and the residue is extracted with dichloromethane (3×30 mL) and water (30 mL). The combined organic layers are dried over sodium sulfate, filtered and concentrated to give a residue that is purified by column chromatography (silica gel, eluent: cyclohexane:ethyl acetate:methanol, 1:3:0 to 0:9:1, v/v/v) to afford {1-[2-(8-methoxy-quinoxalin-2-yloxy)-ethyl]-piperidin-4-yl}-carbamic acid tert-butyl ester as an orange solid (825 mg, 48% yield).
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US08716280B2 |
|---|
| Source dataset | uspto-grants-2014_05 |
|---|
| ORD ID | ord-dab3dfc1a9144b8a89cd194642c8afc2 |
|---|
| Source note | uspto-grants-2014_05 |
|---|